Profile data is unavailable for this security.
About the company
Aptorum Group Limited is United Kingdom-based clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. The Company's business segments include Therapeutics and Non-Therapeutics. Therapeutics segment is engaged in developing various drug molecules and certain technologies for treatment of human disease conditions. Two of the Company’s lead projects, ALS-4 and SACT-1, target infectious disease and cancer, including orphan oncology indications. Non-Therapeutics segment encompasses three businesses: diagnostics projects including PathsDx Test, natural supplements including NativusWell, and AML Clinic. PathsDx Test is a novel molecular-based rapid pathogen identification and detection diagnostics technology, which is under co-development with A*STAR.
- Revenue in USD (TTM)431.38k
- Net income in USD-2.82m
- Incorporated--
- Employees3.00
- LocationAptorum Group Ltd17 Hanover SquareLONDON W1S 1BNUnited KingdomGBR
- Phone+44 208 092 9299
- Fax+44 203 928 8277
- Websitehttp://www.aptorumgroup.com/
More ▼
Mergers & acquisitions
| Acquired company | APM:NAQ since announced | Transaction value |
|---|---|---|
| YOOV Group Holding Ltd | 244.14% | -- |
Data delayed at least 15 minutes, as of May 10 2024 21:00 BST.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Lumos Pharma Inc | 2.05m | -34.03m | 24.51m | 33.00 | -- | 0.8962 | -- | 11.95 | -4.19 | -4.19 | 0.2526 | 3.37 | 0.0363 | -- | 9.47 | 62,151.52 | -60.27 | -29.78 | -68.62 | -32.32 | -- | -- | -1,659.39 | -2,937.61 | -- | -- | 0.00 | -- | 34.67 | -30.31 | -9.57 | -- | -- | -- |
| Cumberland Pharmaceuticals, Inc. | 39.55m | -6.28m | 24.67m | 91.00 | -- | 0.83 | -- | 0.6237 | -0.4448 | -0.4448 | 2.75 | 2.10 | 0.4528 | 0.8383 | 3.45 | 434,643.10 | -7.25 | -7.03 | -10.66 | -9.52 | 84.66 | 79.95 | -16.01 | -17.64 | 1.11 | -25.08 | 0.3041 | -- | -5.85 | 6.15 | -12.73 | -- | -36.17 | -- |
| Oncternal Therapeutics Inc | 785.00k | -39.48m | 25.56m | 27.00 | -- | 0.8471 | -- | 32.56 | -13.44 | -13.44 | 0.2672 | 10.19 | 0.0149 | -- | -- | 29,074.07 | -74.93 | -49.40 | -85.36 | -54.51 | -- | -- | -5,029.17 | -1,342.98 | -- | -- | 0.00 | -- | -47.32 | -- | 10.62 | -- | -- | -- |
| Acasti Pharma Inc | 0.00 | -38.77m | 25.94m | 32.00 | -- | 0.4011 | -- | -- | -5.06 | -5.06 | 0.00 | 6.88 | 0.00 | -- | -- | -- | -40.18 | -45.71 | -41.30 | -50.84 | -- | -- | -- | -69,798.47 | -- | -14.38 | 0.00 | -- | -- | -- | -332.11 | -- | -45.53 | -- |
| Forte Biosciences Inc | 0.00 | -31.48m | 26.51m | 9.00 | -- | 0.7485 | -- | -- | -1.19 | -1.19 | 0.00 | 0.9719 | 0.00 | -- | -- | 0.00 | -77.74 | -72.06 | -84.92 | -82.27 | -- | -- | -- | -491,850.00 | -- | -- | 0.00 | -- | -- | -- | -126.79 | -- | -46.29 | -- |
| Iterum Therapeutics PLC | 0.00 | -38.37m | 26.65m | 14.00 | -- | -- | -- | -- | -2.96 | -2.96 | 0.00 | -0.4743 | 0.00 | -- | -- | 0.00 | -82.44 | -118.12 | -108.84 | -199.23 | -- | -- | -- | -890,554.10 | -- | -- | 1.51 | -- | -- | -- | 13.64 | -- | -32.09 | -- |
| Biora Therapeutics Inc | 4.00k | -124.33m | 26.83m | 58.00 | -- | -- | -- | 6,707.59 | -8.57 | -8.56 | 0.0003 | -4.28 | 0.00009 | -- | 0.0048 | 68.97 | -293.45 | -122.84 | -- | -369.01 | -- | -- | -3,108,350.00 | -415.10 | -- | -- | -- | -- | -98.69 | -87.44 | -154.63 | -- | -53.68 | -- |
| Unity Biotechnology Inc | 0.00 | -39.86m | 26.86m | 19.00 | -- | 0.9457 | -- | -- | -2.75 | -2.75 | 0.00 | 1.69 | 0.00 | -- | -- | 0.00 | -41.95 | -47.21 | -49.03 | -53.51 | -- | -- | -- | -6,395.92 | -- | -- | 0.00 | -- | -100.00 | -- | 10.36 | -- | -61.28 | -- |
| BioVie Inc | 0.00 | -43.27m | 27.32m | 18.00 | -- | 2.65 | -- | -- | -1.19 | -1.19 | 0.00 | 0.188 | 0.00 | -- | -- | 0.00 | -125.99 | -456.35 | -184.48 | -1,810.88 | -- | -- | -- | -- | -- | -- | 0.5764 | -- | -- | -- | -92.67 | -- | -- | -- |
| Aptorum Group Ltd | 431.38k | -2.82m | 27.35m | 3.00 | -- | 1.04 | -- | 63.41 | -0.9126 | -0.9126 | 0.0954 | 4.80 | 0.0208 | 30.36 | 3.88 | 143,793.30 | -20.92 | -40.45 | -19.62 | -42.36 | 2.45 | -4.04 | -1,006.30 | -1,233.68 | 1.18 | -- | 0.1694 | -- | -66.71 | 2.38 | 71.18 | -- | -78.15 | -- |
| America Great Health | 219.13k | -859.20k | 27.45m | 7.00 | -- | -- | -- | 125.26 | -0.00004 | -0.00004 | 0.00001 | -0.0002 | 0.6746 | 0.0721 | 18.16 | 31,304.29 | -265.62 | -543.96 | -- | -- | 95.92 | -247.36 | -393.74 | -1,193.55 | 0.035 | -1.37 | -- | -- | 95.23 | -- | 84.35 | -- | -- | -- |
| Lipocine Inc | -2.85m | -16.35m | 28.02m | 17.00 | -- | 1.37 | -- | -- | -3.11 | -3.11 | -0.5417 | 3.83 | -0.0942 | -- | -- | -167,695.30 | -54.02 | -39.32 | -58.16 | -45.87 | -- | -- | -- | -442.26 | -- | -- | 0.00 | -- | -670.16 | -- | -51.99 | -- | -- | -- |
| NKGen Biotech Inc | 0.00 | -82.95m | 28.12m | 63.00 | -- | -- | -- | -- | -5.24 | -5.24 | 0.00 | -2.68 | 0.00 | -- | -- | 0.00 | -86.93 | -- | -111.69 | -- | -- | -- | -- | -- | -- | -0.6077 | -- | -- | -- | -- | -1,923.83 | -- | -- | -- |
| Aprea Therapeutics Inc | 583.24k | -14.29m | 29.87m | 7.00 | -- | 1.21 | -- | 51.21 | -4.00 | -4.00 | 0.1613 | 4.89 | 0.0221 | -- | -- | 83,320.00 | -54.11 | -68.66 | -63.19 | -77.19 | -- | -- | -2,449.55 | -42,112.84 | -- | -- | 0.00 | -- | -- | -- | 87.32 | -- | 90.61 | -- |
Data as of May 10 2024. Currency figures normalised to Aptorum Group Ltd's reporting currency: US Dollar USD
1.49%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Geode Capital Management LLCas of 31 Dec 2023 | 38.55k | 1.31% |
| Morgan Stanley & Co. LLCas of 31 Dec 2023 | 5.25k | 0.18% |
| NewEdge Advisors LLCas of 31 Dec 2023 | 1.00 | 0.00% |
| UBS Securities LLCas of 31 Dec 2023 | 0.00 | 0.00% |
| PNC Investments LLCas of 31 Dec 2023 | 0.00 | 0.00% |
More ▼
Data from 31 Dec 2023 - 31 Dec 2023Source: FactSet Research Systems Inc.
